Evidence map›Paper›PMID 42085784›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2026

Unpacking boxes: identification of novel inhibitors of malaria parasite invasion.

Claudia Bg Barnes, Molly Parkyn Schneider, Olivia D Ventura, Zahra Razook, Kirsty McCann, Coralie Boulet, Alysha H Literski, Alyssa E Barry, Brad E Sleebs, Brendan S Crabb and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Claudia Bg BarnesBurnet Institute, Melbourne, Victoria, 3004, Australia.
Molly Parkyn SchneiderBurnet Institute, Melbourne, Victoria, 3004, Australia.
Olivia D VenturaBurnet Institute, Melbourne, Victoria, 3004, Australia.
Zahra RazookBurnet Institute, Melbourne, Victoria, 3004, Australia; Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia.
Kirsty McCannBurnet Institute, Melbourne, Victoria, 3004, Australia; Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia.
Coralie BouletBurnet Institute, Melbourne, Victoria, 3004, Australia.
Alysha H LiterskiBurnet Institute, Melbourne, Victoria, 3004, Australia; Monash University, Melbourne, Victoria, 3800, Australia.
Alyssa E BarryBurnet Institute, Melbourne, Victoria, 3004, Australia; Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia.
Brad E SleebsThe Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, 3010, Australia.
Brendan S CrabbBurnet Institute, Melbourne, Victoria, 3004, Australia; Monash University, Melbourne, Victoria, 3800, Australia; Department of Microbiology and Immunology, The University of Melbourne, Parkville, 3010, Australia.
Paul R GilsonBurnet Institute, Melbourne, Victoria, 3004, Australia; Monash University, Melbourne, Victoria, 3800, Australia; Department of Microbiology and Immunology, The University of Melbourne, Parkville, 3010, Australia.
Hayley E BullenBurnet Institute, Melbourne, Victoria, 3004, Australia; Monash University, Melbourne, Victoria, 3800, Australia; Department of Microbiology and Immunology, The University of Melbourne, Parkville, 3010, Australia. Electronic address: Hayley.bullen@burnet.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With resistance to current frontline antimalarial treatments rapidly emerging in malaria endemic regions, there is an urgent need to identify new antimalarial compounds with novel mechanisms of action. Currently, no clinically used antimalarials target erythrocyte invasion, the process by which the short-lived, extracellular merozoite form of Plasmodium falciparum parasites enters a host erythrocyte. Following invasion, the parasite grows and then divides to form a schizont, containing merozoites that exit the host cell and invade new erythrocytes. To identify novel egress and invasion inhibitors, we screened the Medicines for Malaria Venture COVID Box (160 compounds) and Global Health Priority Box (240 compounds). Parasites were treated with the compounds at 1 μM during the egress and invasion period and across both libraries, 20 invasion inhibitors and two partial egress inhibitors were identified. A comparison of the growth IC

Indexed as

AntimalarialsPlasmodium falciparumAnimalsDrug ResistanceErythrocytesHumansInhibitory Concentration 50MerozoitesAntimalarials

Identifiers

PMID42085784
PMCPMC13158776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.